2021 Year in Review - Triple-Negative Breast Cancer
2021 Year in Review - Triple-Negative Breast Cancer | February 18, 2022
Patients with bladder cancer can be empowered to better cope with their diagnosis by providing them with supplemental information relating to their disease state, potential treatments, and patient support services.
2021 Year in Review - Triple-Negative Breast Cancer | February 18, 2022
Responses to first- and second-line chemotherapy regimens for metastatic urothelial carcinoma (mUC) have been less than satisfactory, creating an unmet need for new treatment options for this disease.
2021 Year in Review - Triple-Negative Breast Cancer | February 18, 2022
Patients with endocrine-resistant HR-positive/HER2-negative metastatic breast cancer require novel therapeutic alternatives as a result of the poor outcomes of currently available later-line medications.
2021 Year in Review - Triple-Negative Breast Cancer | February 18, 2022
The emergence of innovative targeted therapy in combination with endocrine therapy has shown improvement in HR-positive breast cancer results, but the US Food and Drug Administration–approved combinations all include endocrine therapies in their regimens, leaving an unmet need in patients who develop endocrine resistance.
2021 Year in Review - Triple-Negative Breast Cancer | January 20, 2022
In the phase 3 ASCENT study, Trodelvy was demonstrated to significantly enhance quality of life compared with standard of care in second-line and beyond metastatic triple-negative breast cancer.
2021 Year in Review - Triple-Negative Breast Cancer | January 20, 2022
Patients need to know why they are taking Trodelvy, the indications for which include metastatic triple-negative breast cancer. They should be educated on the benefits of Trodelvy along with potential side effects associated with treatment, including guidance on how they can manage those adverse events.
2021 Year in Review - Triple-Negative Breast Cancer | January 20, 2022
Trodelvy Access Support is a patient access and reimbursement support program that will help you and your patients understand reimbursement and specific coverage guidelines for Trodelvy.
2021 Year in Review - Triple-Negative Breast Cancer | January 20, 2022
Trodelvy has impressed a number of key opinion leaders across the breast cancer community based on its results in extending overall survival and progression-free survival in patients with metastatic triple-negative breast cancer who have received ≥2 prior therapies, ≥1 in the metastatic setting. It is becoming a preferred therapy for second-line and later metastatic triple-negative breast cancer treatment.
2021 Year in Review - Triple-Negative Breast Cancer | December 14, 2021
Compelling efficacy data for sacituzumab govitecan-hziy results in FDA fast-track approval for its use in metastatic triple-negative breast cancer.
2021 Year in Review - Triple-Negative Breast Cancer | December 14, 2021
Sacituzumab govitecan-hziy has been granted full FDA approval for the treatment of metastatic triple-negative breast cancer. It has also been included in the NCCN Breast Cancer Guidelines based on convincing clinical evidence.
- 1
- 2
Page 1 of 2
Results 1 - 10 of 13
Results 1 - 10 of 13